Go to
current issue
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-09-11 Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Paul G Richardson
Background Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma. Here, we report the findings of the predefined final analysis. Methods GRIFFIN was an open-label, randomised, active-controlled, phase 2 trial
-
Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study Lancet Haematol. (IF 24.7) Pub Date : 2023-09-06 Trine Trab, Joachim Baech, Lasse Hjort Jakobsen, Simon Husby, Marianne Tang Severinsen, Sandra Eloranta, Jette S Gørløv, Judit M Jørgensen, Sif Gudbrandsdottir, Thomas Stauffer Larsen, Peter Brown, Kirsten Grønbæk, Karin E Smedby, Tarec C El-Galaly
Background Second primary malignancies (SPMs) are known complications after chemotherapy, but the risk is not well characterised for patients with lymphoma treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the rate of SPMs in this population relative to matched control individuals from the general population. Methods In this
-
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3 Lancet Haematol. (IF 24.7) Pub Date : 2023-09-06
Abstract not available
-
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation Lancet Haematol. (IF 24.7) Pub Date : 2023-09-06 Anna Sureda, Eva Domingo-Domenech
Abstract not available
-
Revisiting six established practices in the treatment of chronic myeloid leukaemia Lancet Haematol. (IF 24.7) Pub Date : 2023-08-28 Hagop M Kantarjian, Mary Alma Welch, Elias Jabbour
After two decades of use in chronic myeloid leukaemia, the risks and benefits of established treatment practices for BCR::ABL1 tyrosine kinase inhibitors (TKIs) in the chronic myeloid leukaemia in chronic phase of the disease should be analysed. In this Viewpoint, we suggest that the use of lower than approved TKI doses in both front-line and later-line therapies would result in similar treatment efficacy
-
Tackling the enormous global burden of anaemia Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29
Abstract not available
-
Haematological malignancies in pregnancy: time for accurate incidence data Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29 Rudy Birsen, Pierre Pinson, Laurent Chouchana, Ismaël Boussaid, Jean-Marc Treluyer
Abstract not available
-
Haematological malignancies in pregnancy: time for accurate incidence data – Authors' reply Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29 Georgia S Mills
Abstract not available
-
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29 Amar H Kelkar, Shai Shimony, Edward R Scheffer Cliff, Richard M Stone
Abstract not available
-
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results – Authors' reply Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29 Hartmut Döhner, Axel Benner, Arnold Ganser
Abstract not available
-
Against all odds Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29 Brandon Nuechterlein
Abstract not available
-
Understanding the barriers to AML care in India Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29 Jayastu Senapati, Tribikram Panda, Akhil Rajendra, Mukul Aggarwal
Abstract not available
-
Virginia Abello Polo—a once-in-a-lifetime opportunity Lancet Haematol. (IF 24.7) Pub Date : 2023-08-29 Tony Kirby
Abstract not available
-
Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures Lancet Haematol. (IF 24.7) Pub Date : 2023-08-18 Yolba Smit, Sanne J J P M Metsemakers, Jeroen J W M Janssen, Eduardus F M Posthuma, Iris Walraven, Rosella P M G Hermens, Nicole M A Blijlevens
Insight into real-world treatment-related toxic effects reported by patients has the potential to improve care, benchmark trials, and fill knowledge gaps, especially in patients with chronic myeloid leukaemia, which is treated in the majority of patients continually with tyrosine-kinase inhibitors (TKIs). The aim of our systematic review was to investigate the content validity of instruments that elicit
-
Correction to Lancet Haematol 2023; 10: e512–29 Lancet Haematol. (IF 24.7) Pub Date : 2023-08-10
Abstract not available
-
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts Lancet Haematol. (IF 24.7) Pub Date : 2023-08-09 Rory M Shallis, Naval Daver, Jessica K Altman, Rami S Komrokji, Daniel A Pollyea, Talha Badar, Jan P Bewersdorf, Vijaya R Bhatt, Stéphane de Botton, Adolfo de la Fuente Burguera, Hetty E Carraway, Pinkal Desai, Richard Dillon, Nicolas Duployez, Firas El Chaer, Amir T Fathi, Sylvie D Freeman, Ivana Gojo, Michael R Grunwald, Brian A Jonas, Amer M Zeidan
The existence of two acute myeloid leukaemia classification systems—one put forth by WHO and one by the International Consensus Classification in 2022—is concerning. Although both systems appropriately move towards genomic disease definitions and reduced emphasis on blast enumeration, there are consequential disagreements between the two systems on what constitutes a diagnosis of acute myeloid leukaemia
-
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31 Musa Yilmaz, Naval Daver
Abstract not available
-
Optimising treatment of HIV-associated Hodgkin lymphoma Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31 Christian Hoffmann, Marcus Hentrich
Abstract not available
-
Correction to Lancet Haematol 2023; 10: e492–94 Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31
Abstract not available
-
Correction to Lancet Haematol 2023; 10: e585–99 Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31
Abstract not available
-
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31 Paul G Rubinstein, Page C Moore, Milan Bimali, Jeanette Y Lee, Michelle A Rudek, Amy Chadburn, Lee Ratner, David H Henry, Ethel Cesarman, Camille E DeMarco, Dominique Costagliola, Yassine Taoufik, Juan Carlos Ramos, Elad Sharon, Erin G Reid, Richard F Ambinder, Ronald Mitsuyasu, Nicolas Mounier, Caroline Besson, Ariela Noy, Hervé Ghesquières
Background Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been excluded from these studies. We aimed to understand the activity and safety of brentuximab vedotin–AVD in people living with HIV diagnosed with Hodgkin lymphoma, while focusing on HIV
-
Measuring the global burden of anaemia Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31 Sant-Rayn Pasricha, Gemma Moir-Meyer
Abstract not available
-
The challenge of defining the global burden of iron deficiency anaemia Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31 Melissa F Young, Hanqi Luo, Parminder S Suchdev
Abstract not available
-
Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021 Lancet Haematol. (IF 24.7) Pub Date : 2023-07-31
Background Anaemia is a major health problem worldwide. Global estimates of anaemia burden are crucial for developing appropriate interventions to meet current international targets for disease mitigation. We describe the prevalence, years lived with disability, and trends of anaemia and its underlying causes in 204 countries and territories. Methods We estimated population-level distributions of haemoglobin
-
FIT for surgery: fractures, iron, and tranexamic acid Lancet Haematol. (IF 24.7) Pub Date : 2023-07-28 Kazuhiko Ikeda, Kenneth E Nollet
Abstract not available
-
Ferric derisomaltose and tranexamic acid, combined or alone, for reducing blood transfusion in patients with hip fracture (the HiFIT trial): a multicentre, 2 × 2 factorial, randomised, double-blind, controlled trial Lancet Haematol. (IF 24.7) Pub Date : 2023-07-28 Sigismond Lasocki, Xavier Capdevila, Bruno Vielle, Benjamin Bijok, Maria Lahlou-Casulli, Vincent Collange, Nicolas Grillot, Marc Danguy des Deserts, Alexis Duchalais, Bertrand Delannoy, Bertrand Drugeon, Pierre Bouzat, Jean-Stéphane David, Louis Rony, Thibault Loupec, Maxime Léger, Emmanuel Rineau
Background Anaemia and blood transfusion are associated with poor outcomes after hip fracture. We evaluated the efficacy of intravenous iron and tranexamic acid in reducing blood transfusions after hip fracture surgery. Methods In this double-blind, randomised, 2 × 2 factorial trial, we recruited adults hospitalised for hip fractures in 12 medical centres in France who had preoperative haemoglobin
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study Lancet Haematol. (IF 24.7) Pub Date : 2023-07-27 Aaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Ruben Mesa
Background The MOMENTUM study met all key endpoints at week 24, demonstrating symptom, spleen, and anaemia benefits with momelotinib versus danazol in patients with myelofibrosis. In this updated analysis, we report duration of week 24 responses and new responses with momelotinib through week 48. Methods MOMENTUM is an international, double-blind, randomised, phase 3 study done at 107 sites across
-
Maintaining MOMENTUM in myelofibrosis Lancet Haematol. (IF 24.7) Pub Date : 2023-07-27 Marina Kremyanskaya, Bridget K Marcellino
Abstract not available
-
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care Lancet Haematol. (IF 24.7) Pub Date : 2023-07-25 Christian Späth, Thomas Neumann, Christian Andreas Schmidt, Florian Heinrich Heidel, William Hermann Krüger
Allogeneic haematopoietic stem-cell transplantation is a potential curative therapy for otherwise fatal haematological diseases. This treatment modality is complex, burdensome, and can involve considerable or life-threatening adverse events requiring high-quality symptom control. In contrast to patients with solid tumours, the transition to end-of-life care can be abrupt if the underlying disease relapses
-
Optimal haemoglobin concentration in pregnancy Lancet Haematol. (IF 24.7) Pub Date : 2023-07-20 Halimat Olaniyan, Angela C Weyand
Abstract not available
-
Association between maternal haemoglobin concentrations and maternal and neonatal outcomes: the prospective, observational, multinational, INTERBIO-21st fetal study Lancet Haematol. (IF 24.7) Pub Date : 2023-07-20 Eric O Ohuma, Nusrat Jabin, Melissa F Young, Terrence Epie, Reynaldo Martorell, Juan Pablo Peña-Rosas, Maria Nieves Garcia-Casal
Background Anaemia in pregnancy is a global health problem with associated maternal and neonatal morbidity and mortality. We aimed to investigate the association between maternal haemoglobin concentrations during pregnancy and the risk of adverse maternal and neonatal outcomes. Methods In this prospective, observational, multinational, INTERBIO-21st fetal study conducted at maternity units in Brazil
-
Ending the burden of sickle cell disease in Africa Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 Matshidiso R Moeti, Prebo Brango, Juliet Nabyonga-Orem, Benido Impouma
Abstract not available
-
Global advocacy from Zambia for the hopes and dreams of people with sickle cell disease Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 Lwimba Kasongo
Abstract not available
-
Social determinants of health: the next frontier for improving care and outcomes in sickle cell disease Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 Jerlym S Porter, Andrew M Heitzer, Lori E Crosby, Jane S Hankins
Abstract not available
-
Sickle cell disease—unity and patient-centred education Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11
Abstract not available
-
Mental health and psychological resilience in sickle cell disease Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 Marsha J Treadwell
Abstract not available
-
The Lancet Haematology Commission on sickle cell disease: key recommendations Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11
Abstract not available
-
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 Frédéric B Piel, David C Rees, Michael R DeBaun, Obiageli Nnodu, Brigitte Ranque, Alexis A Thompson, Russell E Ware, Miguel R Abboud, Allistair Abraham, Emmanuela E Ambrose, Biree Andemariam, Roshan Colah, Raffaella Colombatti, Nicola Conran, Fernando F Costa, Robert M Cronin, Mariane de Montalembert, Jacques Elion, Erica Esrick, Anthea L Greenway, Kwaku Ohene-Frempong
Abstract not available
-
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 María del Mar Mañú Pereira, Raffaella Colombatti, Federico Alvarez, Pablo Bartolucci, Celeste Bento, Angelo Loris Brunetta, Elena Cela, Soteroula Christou, Anna Collado, Mariane de Montalembert, Laurence Dedeken, Pierre Fenaux, Frédéric Galacteros, Andreas Glenthøj, Victoria Gutiérrez Valle, Antonis Kattamis, Joachim Kunz, Stephan Lobitz, Corrina McMahon, Mariangela Pellegrini, Béatrice Gulbis
Sickle cell disease is a hereditary multiorgan disease that is considered rare in the EU. In 2017, the Rare Diseases Plan was implemented within the EU and 24 European Reference Networks (ERNs) were created, including the ERN on Rare Haematological Diseases (ERN-EuroBloodNet), dedicated to rare haematological diseases. This EU initiative has made it possible to accentuate existing collaborations and
-
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 Isaac Odame
Abstract not available
-
Sickle cell disease in the Caribbean: progress in newborn screening, clinical care, and research through collaboration Lancet Haematol. (IF 24.7) Pub Date : 2023-07-11 Jennifer Knight-Madden, Monika Asnani, Lesley King, Marie-Dominique Hardy-Dessources
Abstract not available
-
International Society on Thrombosis and Haemostasis Congress 2023 Lancet Haematol. (IF 24.7) Pub Date : 2023-07-10 Emma Cookson
Abstract not available
-
European Hematology Association 2023 Hybrid Congress Lancet Haematol. (IF 24.7) Pub Date : 2023-07-07 Yaiza del Pozo Martín
Abstract not available
-
Burnout in the haematological workforce Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03
Abstract not available
-
More opportunities to advance paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Lindsey Murphy, Ibrahim Aldoss
Abstract not available
-
Concerns on perioperative anaemia management in the FIT trial Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Verena Petzer, Günter Weiss
Abstract not available
-
Concerns on perioperative anaemia management in the FIT trial Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Tomohiko Sato, Kohei Uno, Kotaro Kida
Abstract not available
-
The essential role of randomised controlled trials Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Bernard L Marini, Aaron M Goodman, Anthony J Perissinotti
Abstract not available
-
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Rohan Halder, Varsha Mishra, Tribikram Panda, Narendra Agrawal, Dinesh Bhurani
Abstract not available
-
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Motoharu Shibusawa, Tetsuya Tanimoto
Abstract not available
-
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome – Authors' reply Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Stephan A Grupp
Abstract not available
-
Correction to Lancet Haematol 2023; 10: e213–24 Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03
Abstract not available
-
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Emma Wilkinson
Abstract not available
-
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Carmelo Gurnari, Manuela Spadea, Rafaella Muratori, Valentine Jimenez, Vera Radici, Sheila Torrado, Nihar Desai, Julio Ropero, Ibrahim N Muhsen, Azada Ibrahimova, Justin Du Toit, Candice Laverne Hendricks, Nico Gagelmann, Claire Horga
Abstract not available
-
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Stephen P Hunger, Thai Hoa Tran, Vaskar Saha, Meenakshi Devidas, Maria Grazia Valsecchi, Julie M Gastier-Foster, Giovanni Cazzaniga, Shalini C Reshmi, Michael J Borowitz, Anthony V Moorman, Nyla A Heerema, Andrew J Carroll, Patricia Martin-Regueira, Mignon L Loh, Elizabeth A Raetz, Kirk R Schultz, William B Slayton, Gunnar Cario, Martin Schrappe, Lewis B Silverman, Andrea Biondi
Background The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib, a second-generation ABL-class inhibitor, with intensive chemotherapy in children with newly diagnosed Ph-positive acute lymphoblastic leukaemia. Methods
-
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Jake S O’Donnell, Stewart K Hunt, Keith J Chappell
The human T-lymphotropic virus type 1 (HTLV-1) retrovirus infects 10–20 million people globally, with endemic regions in southwestern Japan, the Caribbean basin, Africa, and central Australia. HTLV-1 is associated with lifelong infection and immune suppression, resulting in a range of serious sequalae, including adult T-cell leukaemia or lymphoma (ATLL) in 5% of cases. To date, there are no preventive
-
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity? Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Gianpietro Semenzato, Irene M Ghobrial, Paolo Ghia
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance are three premalignant conditions characterised by the presence of small clonal cell expansions in individuals without symptoms or signs that distinguish the related overt malignancies (chronic lymphocytic leukaemia, multiple myeloma, and T-cell large granular lymphocytic
-
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-07-03 Li Xuan, Yu Wang, Kaibo Yang, Ruoyang Shao, Fen Huang, Zhiping Fan, Peiru Chi, Yajing Xu, Na Xu, Lan Deng, Xudong Li, Xinquan Liang, Xiaodan Luo, Pengcheng Shi, Hui Liu, Zhixiang Wang, Ling Jiang, Ren Lin, Yan Chen, Sanfang Tu, Qifa Liu
Background Our open-label, multicentre, randomised, phase 3 trial showed that sorafenib maintenance after haematopoietic stem-cell transplantation (HSCT) improved overall survival and reduced relapse for patients with FLT3 internal tandem duplication (FLT3-ITD) acute myeloid leukaemia undergoing allogeneic HSCT. Here, we present a post-hoc analysis on the 5-year follow-up data of this trial. Methods
-
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem Lancet Haematol. (IF 24.7) Pub Date : 2023-06-26 Frank W G Leebeek
Abstract not available
-
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial Lancet Haematol. (IF 24.7) Pub Date : 2023-06-26 Margaret V Ragni, Scott D Rothenberger, Robert Feldman, Danielle Nance, Andrew D Leavitt, Lynn Malec, Roshni Kulkarni, Robert Sidonio, Eric Kraut, Joseph Lasky, Rajiv Pruthi, Dana Angelini, Claire Philipp, Nina Hwang, Allison P Wheeler, Craig Seaman, Nicoletta Machin, Frederico Xavier, Michael Meyer, Daniel Bellissimo, Andrew D Althouse
Background Heavy menstrual bleeding occurs in 80% of women with von Willebrand disease and is associated with iron deficiency and poor response to current therapies. International guidelines indicate low certainty regarding effectiveness of hormonal therapy and tranexamic acid. Although von Willebrand factor (VWF) concentrate is approved for bleeds, no prospective trials guide its use in heavy menstrual
更新日期：2023-08-01
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号